TRIMPEX 200
LOE ApproachingNDAORALTABLET
Approved
May 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIMPEX 200 is an oral tablet NDA approved by Roche in 1980 with mechanism of action and indications not currently disclosed in available data. The drug's 44-year market presence suggests established clinical utility in a chronic or recurrent condition amenable to oral dosing.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating downsizing brand teams and shift toward generic transition and cost management roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRIMPEX 200 offers defensive career positioning focused on mature product stewardship, cost management, and market access optimization rather than growth. This is ideal for professionals seeking stability and deep therapeutic expertise in a stable specialty market before potential divestiture or generic transition.
Brand Manager (legacy product management)Senior Medical Science Liaison
Worked on TRIMPEX 200 at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.